Moderna (MRNA) Stock Forecast & Price Target

Compare

17,337 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRNA Analyst Ratings

Hold

4 Buy

13 Hold

3 Sell

Based on 20 analysts giving stock ratings to

Moderna

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$48.07

▲(49.29%Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $48.07 with a high forecast of $198.00 and a low forecast of $25.00. The average price target represents a 49.29% change from the last price of $32.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","199":"$199","67.75":"$67.8","111.5":"$111.5","155.25":"$155.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,67.75,111.5,155.25,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.69,41.713846153846156,54.73769230769231,67.76153846153846,80.78538461538461,93.80923076923077,106.83307692307693,119.85692307692308,132.88076923076923,145.9046153846154,158.92846153846153,171.9523076923077,184.97615384615386,{"y":198,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.69,30.180769230769233,31.67153846153846,33.16230769230769,34.653076923076924,36.143846153846155,37.63461538461539,39.12538461538462,40.61615384615385,42.10692307692308,43.597692307692306,45.08846153846154,46.57923076923077,{"y":48.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.69,28.40615384615385,28.122307692307693,27.83846153846154,27.554615384615385,27.270769230769233,26.986923076923077,26.703076923076924,26.41923076923077,26.135384615384616,25.85153846153846,25.567692307692308,25.283846153846152,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":115.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.17,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.58,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":30.96,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$198.00

Average Price Target$48.07

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$35

Hold

8.70%

Upside

Reiterated

07/11/25

Moderna's financial performance is the most significant factor affecting its stock score, with substantial declines in revenue and profitability. Technical indicators provide some positive momentum, but valuation remains weak due to negative earnings. Despite strategic cost reductions and market expansions, challenges persist, particularly in revenue generation and regulatory hurdles.

Jessica FyeJ.P. Morgan

J.P. Morgan

$26

Sell

-19.25%

Downside

Reiterated

07/17/25

Moderna (MRNA) Receives a Sell from J.P. Morgan

Terence FlynnMorgan Stanley

Morgan Stanley

$31

Hold

-3.73%

Downside

Reiterated

07/10/25

Morgan Stanley Remains a Hold on Moderna (MRNA)

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

$198

Buy

514.91%

Upside

Reiterated

07/10/25

Brookline Capital Markets Keeps Their Buy Rating on Moderna (MRNA)

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Bernstein Remains a Hold on Moderna (MRNA)

Luca IssiRBC Capital

RBC Capital

$28

Hold

-13.04%

Downside

Reiterated

07/07/25

Moderna (MRNA) Receives a Hold from RBC Capital

Myles MinterWilliam Blair

William Blair

―

Hold

―

Reiterated

07/05/25

William Blair Remains a Hold on Moderna (MRNA)

Salveen RichterGoldman Sachs

Goldman Sachs

$35

Hold

8.70%

Upside

Reiterated

06/30/25

Cautious Outlook on Moderna: Promising Vaccine Data Overshadowed by Regulatory and Financial Uncertainties

Mani ForooharLeerink Partners

Leerink Partners

―

Sell

―

Reiterated

06/30/25

Leerink Partners Reaffirms Their Sell Rating on Moderna (MRNA)

Tyler Van BurenTD Cowen

TD Cowen

$30

Hold

-6.83%

Downside

Reiterated

06/26/25

TD Cowen Remains a Hold on Moderna (MRNA)

Gena WangBarclays

Barclays

$40

Hold

24.22%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Demant (Other OTC: WILLF), Moderna (NASDAQ: MRNA) and Arcellx Inc (NASDAQ: ACLX)

Geoff MeachamCiti

Citi

$32

Hold

-0.62%

Downside

Reiterated

06/13/25

Moderna's mRESVIA Vaccine Faces Market Challenges Despite FDA Approval

Edward TenthoffPiper Sandler

Piper Sandler

$69

Buy

114.29%

Upside

Reiterated

06/13/25

Piper Sandler Remains a Buy on Moderna (MRNA)

Tim AndersonBank of America Securities

Bank of America Securities

$26

Sell

-19.25%

Downside

Reiterated

06/06/25

Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA)

Jasper HellwegArgus Research

Argus Research

―

Hold

―

Reiterated

05/23/25

Moderna (MRNA) Gets a Hold from Argus Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$35

Hold

8.70%

Upside

Reiterated

07/11/25

Jessica FyeJ.P. Morgan

J.P. Morgan

$26

Sell

-19.25%

Downside

Reiterated

07/17/25

Moderna (MRNA) Receives a Sell from J.P. Morgan

Terence FlynnMorgan Stanley

Morgan Stanley

$31

Hold

-3.73%

Downside

Reiterated

07/10/25

Morgan Stanley Remains a Hold on Moderna (MRNA)

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

$198

Buy

514.91%

Upside

Reiterated

07/10/25

Brookline Capital Markets Keeps Their Buy Rating on Moderna (MRNA)

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Bernstein Remains a Hold on Moderna (MRNA)

Luca IssiRBC Capital

RBC Capital

$28

Hold

-13.04%

Downside

Reiterated

07/07/25

Moderna (MRNA) Receives a Hold from RBC Capital

Myles MinterWilliam Blair

William Blair

―

Hold

―

Reiterated

07/05/25

William Blair Remains a Hold on Moderna (MRNA)

Salveen RichterGoldman Sachs

Goldman Sachs

$35

Hold

8.70%

Upside

Reiterated

06/30/25

Cautious Outlook on Moderna: Promising Vaccine Data Overshadowed by Regulatory and Financial Uncertainties

Mani ForooharLeerink Partners

Leerink Partners

―

Sell

―

Reiterated

06/30/25

Leerink Partners Reaffirms Their Sell Rating on Moderna (MRNA)

Tyler Van BurenTD Cowen

TD Cowen

$30

Hold

-6.83%

Downside

Reiterated

06/26/25

TD Cowen Remains a Hold on Moderna (MRNA)

Gena WangBarclays

Barclays

$40

Hold

24.22%

Upside

Reiterated

06/17/25

Analysts Offer Insights on Healthcare Companies: Demant (Other OTC: WILLF), Moderna (NASDAQ: MRNA) and Arcellx Inc (NASDAQ: ACLX)

Geoff MeachamCiti

Citi

$32

Hold

-0.62%

Downside

Reiterated

06/13/25

Moderna's mRESVIA Vaccine Faces Market Challenges Despite FDA Approval

Edward TenthoffPiper Sandler

Piper Sandler

$69

Buy

114.29%

Upside

Reiterated

06/13/25

Piper Sandler Remains a Buy on Moderna (MRNA)

Tim AndersonBank of America Securities

Bank of America Securities

$26

Sell

-19.25%

Downside

Reiterated

06/06/25

Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA)

Jasper HellwegArgus Research

Argus Research

―

Hold

―

Reiterated

05/23/25

Moderna (MRNA) Gets a Hold from Argus Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

1 Month

xxx

Success Rate

26/43 ratings generated profit

Average Return

+0.14%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.47% of your transactions generating a profit, with an average return of +0.14% per trade.

3 Months

xxx

Success Rate

26/43 ratings generated profit

Average Return

-7.18%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.47% of your transactions generating a profit, with an average return of -7.18% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

34/43 ratings generated profit

Average Return

-4.28%

reiterated a sell rating 19 days ago

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 79.07% of your transactions generating a profit, with an average return of -4.28% per trade.

2 Years

xxx

Success Rate

38/43 ratings generated profit

Average Return

+30.40%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.37% of your transactions generating a profit, with an average return of +30.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRNA has received 6 Buy Ratings, 34 Hold Ratings, and 7 Sell Ratings. MRNA average Analyst price target in the past 3 months is 48.07.

Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$2.98 with a range of -$3.58 to -$2.63. The previous quarter’s EPS was -$2.52. MRNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $114.40M with a range of $67.80M to $158.00M. The previous quarter’s sales results were $108.00M. MRNA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Moderna’s 12-month average price target is 48.07.

What is MRNA’s upside potential, based on the analysts’ average price target?

Moderna has 49.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRNA a Buy, Sell or Hold?

Moderna has a consensus rating of Hold which is based on 4 buy ratings, 13 hold ratings and 3 sell ratings.

What is Moderna’s price target?

The average price target for Moderna is 48.07. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $198.00 ,the lowest forecast is $25.00. The average price target represents 49.29% Increase from the current price of $32.2.

What do analysts say about Moderna?

Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of MRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Moderna (MRNA) Stock Forecast & Price Target

MRNA Analyst Ratings

MRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Moderna

MRNA Analyst Recommendation Trends

MRNA Financial Forecast

MRNA Earnings Forecast

MRNA Sales Forecast

MRNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts